The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab

Clinical Colorectal Cancer

Volumn 12, Issue 4, 2013, Pages

  Strimpakos, Alexios ^a   Pentheroudakis, George ^b   Kotoula, Vassiliki ^c   De Roock, Wendy ^d   Kouvatseas, George ^e   Papakostas, Pavlos ^f   Makatsoris, Thomas ^g   Papamichael, Demetris ^h   Andreadou, Anna ^c   Sgouros, Joseph ⁱ   Zizi Sermpetzoglou, Adamantia ^j   Kominea, Athina ^k   Televantou, Despina ^c   Razis, Evangelia ^l   Galani, Eleni ^m   Pectasides, Dimitrios ^f   Tejpar, Sabine ^d   Syrigos, Konstantinos ^a   Fountzilas, George ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Health Data Specialists Ltd   (Greece)

^f HIPPOKRATION HOSPITAL   (Greece)

^g UNIVERSITY OF PATRAS   (Greece)

^h Bank of Cyprus Group Oncology Centre   (Cyprus)

ⁱ AGII ANARGIRI CANCER HOSPITAL   (Greece)

^j TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^k Aegion General Hospital   (Greece)

^l HYGEIA HOSPITAL   (Greece)

^m METROPOLITAN HOSPITAL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BINDING PROTEIN; CETUXIMAB; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FLUOROPYRIMIDINE; FORMALDEHYDE; GROWTH FACTOR RECEPTOR; IRINOTECAN; K RAS PROTEIN; MESSENGER RNA; OXALIPLATIN; PARAFFIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR BIOPSY; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EPHRIN-A2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84887317804     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.07.001     Document Type: Article

References (45)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics 2010 CA Cancer J Clin 60 2010 277 300
2. S. Manfredi, and A.M. Bouvier Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population Br J Surg 93 2006 1115 1122
3. A.B. Benson III Epidemiology disease progression and economic burden of colorectal cancer J Manag Care Pharm 13 2007 S5 18
4. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
5. D. Cunningham, and B. Glimelius A phase III study of irinotecan CPT-11 versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group Semin Oncol 26 1999 6 12
6. P. Bossi, G. Viale, and A.K. Lee Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations Cancer Res 55 1995 5049 5053
7. L.F. Brown, B. Berse, and R.W. Jackman Expression of vascular permeability factor vascular endothelial growth factor and its receptors in adenocarcinomas of the gastrointestinal tract Cancer Res 53 1993 4727 4735
8. J.A. McKay, L.J. Murray, and S. Curran Evaluation of the epidermal growth factor receptor EGFR in colorectal tumours and lymph node metastases Eur J Cancer 38 2002 2258 2264
9. J.P. Spano, C. Lagorce, and D. Atlan Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 2005 102 108
10. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
11. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
12. H.J. Lenz, E. Van Cutsem, and S. Khambata-Ford Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan oxaliplatin and fluoropyrimidines J Clin Oncol 24 2006 4914 4921
13. A. Lievre, J.B. Bachet, and D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
14. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
15. L. Mishra, B. Bass, and B.S. Ooi Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers Growth Horm IGF Res 8 1998 473 479
16. T. Winder, W. Zhang, and D. Yang Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS MCRC patients Clin Cancer Res 16 2010 5591 5602
17. M. Scartozzi, A. Mandolesi, and R. Giampieri Insulin-like growth factor 1 expression correlates with clinical outcome in K-ras wild type colorectal cancer patients treated with cetuximab and irinotecan Int J Cancer 127 2010 1941 1947
18. P. Kountourakis, K. Pavlakis, and A. Psyrri Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas BMC Cancer 6 2006 46
19. D.L. Wheeler, S. Huang, and T.J. Kruser Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 2008 3944 3956
20. N.I. Herath, M.D. Spanevello, and J.D. Doecke Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis Eur J Cancer 48 2012 753 762
21. T. Saito, N. Masuda, and T. Miyazaki Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis Oncol Rep 11 2004 605 611
22. V. Kotoula, S. Lambaki, and D. Televantou STAT-related profiles are associated with patient response to targeted treatments in locally advanced SCCHN Transl Oncol 4 2011 47 58
23. I. Sanchez-Navarro, A. Gamez-Pozo, and M. Gonzalez-Baron Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed paraffin-embedded breast cancer tissues Biotechniques 48 2010 389 397
24. A.K. Koutras, K.T. Kalogeras, and M.A. Dimopoulos Evaluation of the prognostic and predictive value of HER family MRNA Expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) Study Br J Cancer 99 2008 1775 1785
25. M. Nishino, J.P. Jagannathan, N.H. Ramaiya, and A.D. Van den Abbeele Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know AJR Am J Roentgenol 195 2010 281 289
26. A. Inno, M. Di Salvatore, and T. Cenci Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10 2011 325 332
27. F. Huang, L.A. Xu, and S. Khambata-Ford Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer Clin Cancer Res 18 2012 1156 1166
28. F. Cappuzzo, M. Varella-Garcia, and G. Finocchiaro Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Br J Cancer 99 2008 83 89
29. C. Horndler, R. Gallego, and X. Garcia-Albeniz Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (PIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD Study Cancer Biol Ther 11 2011 177 183
30. S. Heindl, E. Eggenstein, and S. Keller Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines J Cancer Res Clin Oncol 2012 Jan 31 [Epub ahead of print]
31. M. Scartozzi, R. Giampieri, and E. Maccaroni Analysis of HER-3 insulin growth factor-1 nuclear factor-KB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-ras wild-type colorectal cancer patients receiving irinotecan-cetuximab Ann Oncol 23 2012 1706 1712
32. M. Scartozzi, A. Mandolesi, and R. Giampieri The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab Oncologist 16 2011 53 60
33. V. Martin, L. Landi, and F. Molinari HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients Br J Cancer 108 2013 668 675
34. S. Khambata-Ford, C.R. Garrett, and N.J. Meropol Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 2007 3230 3237
35. B. Jacobs, W. De Roock, and H. Piessevaux Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 27 2009 5068 5074
36. Z. Saridaki, M. Tzardi, and C. Papadaki Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG, expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients PLoS One 6 2011 e15980
37. J.B. Baker, D. Dutta, and D. Watson Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer Br J Cancer 104 2011 488 495
38. E.B. Pasquale Eph receptors and ephrins in cancer: bidirectional signalling and beyond Nat Rev Cancer 10 2010 165 180
39. M. Heroult, F. Schaffner, and H.G. Augustin Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression Exp Cell Res 312 2006 642 650
40. J.P. Himanen, and D.B. Nikolov Eph receptors and ephrins Int J Biochem Cell Biol 35 2003 130 134
41. N.I. Herath, and A.W. Boyd The role of Eph receptors and ephrin ligands in colorectal cancer Int J Cancer 126 2010 2003 2011
42. R.C. Ireton, and J. Chen EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr Cancer Drug Targets 5 2005 149 157
43. D.M. Brantley, N. Cheng, and E.J. Thompson Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo Oncogene 21 2002 7011 7026
44. K. Carles-Kinch, K.E. Kilpatrick, J.C. Stewart, and M.S. Kinch Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior Cancer Res 62 2002 2840 2847
45. M.S. Duxbury, H. Ito, and M.J. Zinner Ligation of EphA2 by ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness Biochem Biophys Res Commun 320 2004 1096 1102